The role of sialic acid in the formation of protective conformational bacterial polysaccharide epitopes

Anticarbohydrate Antibodies: From Molecular Basis to Clinical Application

Volumn 9783709108703, Issue , 2012, Pages 55-73

  Jennings, Harold J ^a  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84930583039     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-7091-0870-3_3     Document Type: Chapter

References (60)

1. Ashton FE, Ryan JA, Michon F, Jennings HJ. (1989). Protective efficacy of mouse serum to the N-propionyl derivative of meningococcal group B polysaccharide. Microb Pathog 6: 455-458
2. Baker CJ, Kasper DL. (1976). Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med 294: 753-756
3. Baker CJ, Kasper DL. (1985). Group B streptococcal vaccines. Rev Infect Dis 7: 458-467
4. Baumann H, Brisson JR, Michon F, Pon R, Jennings HJ. (1993). Comparison of the conformation of the epitope of a (2-8) polysialic acid with its reduced and N-acyl derivatives. Biochemistry 32: 4007-4013
5. Bhattacharjee AK, Jennings HJ, Kenny CP, Martin A, Smith ICP. (1975). Structural determination of the sialic acid polysaccharide antigens of Neisseria meningitidis serogroups B and C with carbon 13 nuclear magnetic resonance. J Biol Chem 250: 1926-1932
6. Brisson JR, Baumann H, Imberty A, Perez S, Jennings HJ. (1992). Helical epitope of the group B meningococcal a (2-8) -linked sialic acid polysaccharide. Biochemistry 31: 4996-5004
7. Brisson JR, Uhrinova S, Woods RJ, van Der Zwan M, Jarrell HC, Paoletti LC, Kasper DL, Jennings HJ. (1997). NMR and molecular dynamics studies of the conformational epitope of the type III group B Streptococcus capsular polysaccharide and derivatives. Biochemistry 36: 3278-3292
8. Bruge J, Moulin JC, Danve B, Dalla Longa N, Valentin C, Goldman C, Rougon G, Herman JP, Coquet B, Thoinet M, Schulz D. (1996). Evaluation of the innocuity of a group B meningococcal polysaccharide conjugate in hyperimmunized, pregnant cynomolgus monkeys and their offspring. In: Zollinger W, Frasch CE, Deal CD (eds) Tenth international pathogenic Neisseria conference abstracts, Baltimore, pp 222-223
9. Bruge J, Bouveret-Le-Cam N, Danve B, Rougon G, Schulz D. (2004). Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers. Vaccine 22: 1087-1096
10. Devi SJN, Robbins JB, Schneerson R. (1991). Antibodies to poly [ (2-8) -a-N-acetylneuraminic acid] and poly [ (2-9) -a-N-acetylneuraminic acid] are elicited by immunization of mice with Escherichia coli K92 conjugates: potential vaccines for groups B and C meningococci and E. coli K1. Proc Natl Acad Sci USA 88: 7175-7179
11. Edwards MS, Kasper DL, Jennings HJ, Baker CJ, Nicholson-Weller A. (1982). Capsular sialic acid prevents activation of the alternative complement pathway by type III, group B streptococci. J Immunol 128: 1278-1283
12. Egan W, Liu TY, Dorow D, Cohen JS, Robbins JD, Gotschlich EC, Robbins JB. (1977). Structural studies on the sialic acid polysaccharide antigen of Escherichia coli strain Bos-12. Biochemistry 16: 3687-3692
13. Evans SV, Sigurskjold BW, Jennings HJ, Brisson JR, To R, Tse WC, Altman E, Frosch M, Weisgerber C, Kratzin HD, Klebert S, Vaesen M, Bitter-Suermann D, Rose DR, Young NM, Bundle DR. (1995). Evidence for the extended helical nature of polysaccharide epitopes. The 2.8 A resolution structure and thermodynamics of ligand binding of an antigen binding fragment specific for a- (2-8) -polysialic acid. Biochemistry 34: 6737-6744
14. Finne J, Finne U, Deagostini-Bazin H, Goridis C. (1983). Occurrence of a (2-8) linked polysialosyl units in a neural cell adhesion molecule. Biochem Biophys Res Commun 112: 482-487
15. Finne J, Mäkelä PH. (1985). Cleavage of the polysialosyl units of brain glycoproteins by a bacteriophage endosialidase. Involvement of a long oligosaccharide segment in molecular interactions of polysialic acid. J Biol Chem 260: 1265-1270
16. Frosch M, Gorgen I, Boulnois GJ, Timmis KN, Bitter-Suermann D. (1985). NZB mouse system for production of monoclonal antibodies to weak bacterial antigens: isolation of an IgG antibody to the polysaccharide capsules of Escherichia coli K1 and group B meningococci. Proc Natl Acad Sci USA 82: 1194-1198
17. Fusco PC, Michon F, Tai JY, Blake MS. (1997). Preclinical evaluation of a novel group B meningococcal conjugate vaccine that elicits bactericidal activity in both mice and nonhuman primates. J Infect Dis 175: 364-372
18. Gotschlich EC, Fraser BA, Nishimura O, Robbins JB, Liu TY. (1981). Lipid on capsular polysaccharides of gram-negative bacteria. J Biol Chem 256: 8915-8921
19. Guttormsen HK, Paoletti LC, Mansfield KG, Jachymek W, Jennings HJ, Kasper DL. (2008). Rational chemical design of the carbohydrate in a glycoconjugate vaccine enhances IgMto- IgG switching. Proc Natl Acad Sci USA 105: 5903-5908
20. Hayrinen J, Bitter-Suermann D, Finne J. (1989). Interaction of meningococcal group B monoclonal antibody and its Fab fragment with a 2-8-linked sialic acid polymers: requirement of a long oligosaccharide segment for binding. Mol Immunol 26: 523-529
21. Hayrinen J, Jennings H, Raff HV, Rougon G, Hanai N, Gerardy-Schahn R, Finne J. (1995). Antibodies to polysialic acid and its N-propyl derivative: binding properties and interaction with human embryonal brain glycopeptides. J Infect Dis 171: 1481-1490
22. Jennings HJ. (1983). Capsular polysaccharides as human vaccines. Adv Carbohydr Chem Biochem 41: 155-208
23. Jennings HJ, Lugowski C (1981a) Immunochemistry of groups A, B and C meningococcal polysaccharide-tetanus toxoid conjugates. J Immunol 127: 1012-1018
24. Jennings HJ, Lugowski C, Kasper DL (1981b) Conformational aspects critical to the immunospecificity of the type III group B streptococcal polysaccharide. Biochemistry 20: 4511-4518
25. Jennings HJ, Katzenellenbogen E, Lugowski C, Michon F, Roy R, Kasper DL. (1984). Structure, conformation, and immunology of sialic acid-containing polysaccharides of human pathogenic bacteria. Pure Appl Chem 56: 893-905
26. Jennings HJ, Roy R, Michon F. (1985). Determinant specificities of the groups B and C polysaccharides of Neisseria meningitidis. J Immunol 134: 2651-2657
27. Jennings HJ, Roy R, Gamian A. (1986). Induction of meningococcal group B polysaccharidespecific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine. J Immunol 137: 1708-1713
28. Jennings HJ, Gamian A, Ashton FE. (1987). N-propionylated group B meningococcal polysaccharide mimics a unique epitope on group B Neisseria meningitidis. J Exp Med 165: 1207-1211
29. Jennings HJ, Gamian A, Michon F, Ashton FE. (1989). Unique intermolecular bactericidal epitope involving the homosialopolysaccharide capsule on the cell surface of group B Neisseria meningitidis and Escherichia coli K1. J Immunol 142: 3585-3591
30. Jennings HJ. (1997). N-propionylated group B meningococcal polysaccharide glycoconjugate vaccine against group B meningococcal meningitis. Int J Infect Dis 1: 158-164
31. Kabat EA. (1976). Structural concepts in immunology and immunochemistry, 2nd edn. Holt, Rinehart, and Winston, New York, pp 241-267
32. Kabat EA, Nickerson KG, Liao J, Grossbard L, Osserman EF, Glickman E, Chess L, Robbins JB, Schneerson R, Yang YH. (1986). A human monoclonal macroglobulin with specificity for a- (2-8) -linked poly-N-acetylneuraminic acid, the capsular polysaccharide of group B meningococci and Escherichia coli K1, which crossreacts with polynucleotides and with denatured DNA. J Exp Med 164: 642-654
33. Kabat EA, Liao J, Osserman EF, Gamian A, Michon F, Jennings HJ. (1988). The epitope associated with the binding of the capsular polysaccharide of the group B meningococcus and of Escherichia coli K1 to a human monoclonal macroglobulin, IgMNOV. J Exp Med 168: 699-711
34. Kadirvelraj R, Gonzalez OJ, Foley BL, Beckham ML, Jennings HJ, Foote S, Ford MG, Woods RJ. (2006). Understanding the bacterial polysaccharide antigenicity of Streptococcus agalactiae versus Streptococcus pneumoniae. Proc Natl Acad Sci USA 103: 8149-8154
35. Kasper DL, Baker CJ, Baltimore RS, Crabb JH, Schiffman G, Jennings HJ. (1979). Immunodeterminant specificity of human immunity to type III group B Streptococcus. J Exp Med 149: 327-339
36. Kogan G, Brisson JR, Kasper DL, von Hunolstein C, Orefici G, Jennings HJ. (1995). Structural elucidation of the novel type VII group B Streptococcus capsular polysaccharide by high resolution NMR spectroscopy. Carbohydr Res 277: 1-9
37. Krug LM, Ragupathi G, Ng KK, Hood C, Jennings HJ, Guo Z, Kris MG, Miller V, Pizzo B, Tyson L, Baez V, Livingston PO. (2004). Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyanin. Clin Cancer Res 10: 916-923
38. Lewis AL, Nizet V, Varki A. (2004). Discovery and characterization of sialic acid O-acetylation in group B Streptococcus. Proc Natl Acad Sci USA 101: 11123-11128
39. MacKenzie CR, Jennings HJ. (2003). Characterization of polysaccharide conformational epitopes by surface plasmon resonance. Methods Enzymol 363: 340-354
40. Michon F, Brisson JR, Jennings HJ. (1987). Conformational differences between linear a- (2-8) - linked homosialooligosaccharides and the epitope of the group B meningococcal polysaccharide. Biochemistry 26: 8399-8405
41. Orskov F, Orskov I, Sutton A, Schneerson R, Lin W, Egan W, Hoff GE, Robbins JB. (1979). Form variation in Escherichia coli K1: determined by O-acetylation of the capsular polysaccharide. J Exp Med 149: 669-685
42. Paoletti LC, Wessels MR, Michon F, DiFabio JL, Jennings HJ, Kasper DL. (1992). Group B Streptococcus type II polysaccharide - tetanus toxoid conjugate vaccine. Infect Immun 60: 4009-4014
43. Paoletti LC, Wessels MR, Rodewald AK, Shroff AA, Jennings HJ, Kasper DL. (1994). Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine. Infect Immun 62: 3236-3243
44. Paoletti LC, Kasper DL. (2003). Glycoconjugate vaccines to prevent group B streptococcal infections. Expert Opin Biol Ther 3: 975-984
45. Patenaude SI, Vijay SM, Yang QL, Jennings HJ, Evans SV. (1998). Crystallization and preliminary X-ray diffraction analysis of antigen-binding fragments which are specific for antigenic conformations of sialic acid homopolymers. Acta Crystallogr D Biol Crystallogr 54: 1005-1007
46. Peltola H. (1998). Meningococcal vaccines. Current status and future possibilities. Drugs 55: 347-366
47. Pon RA, Lussier M, Yang QL, Jennings HJ. (1997). N-propionylated group B meningococcal polysaccharide mimics a unique bactericidal capsular epitope in group B Neisseria meningitidis. J Exp Med 185: 1929-1938
48. Pon RA, Khieu NH, Yang QL, Brisson JR, Jennings HJ. (2002). Serological and conformational properties of E. coli K92 capsular polysaccharide and its N-propionylated derivative both illustrate that induced antibody does not recognize extended epitopes of polysialic acid: Implications for a comprehensive conjugate vaccine against groups B and C N. meningitidis. Can J Chem 80: 1055-1063
49. Pon RA, Jennings HJ. (2008). Carbohydrate-based antibacterial vaccines. In: Guo Z, Boons GJ (eds) Carbohydrate-based vaccines and immunotherapies. Wiley, Hoboken, pp 117-166
50. Raff HV, Devereux D, Shuford W, Abbott-Brown D, Maloney G. (1988). Human monoclonal antibody with protective activity for Escherichia coli K1 and Neisseria meningitidis group B infections. J Infect Dis 157: 118-126
51. Roth J, Zuber C, Komminoth P, Scheidegger EP, Warhol MJ, Bitter-Suermann D, Heitz PU. (1993). Expression of polysialic acid in human tumors and its significance for tumor growth. In: Roth J, Rutishauser U, Troy FA (eds) Polysialic acid: from microbes to man. Birkhauser, Basel, pp 335-348
52. Rougon G, Dubois C, Buckley N, Magnani JL, Zollinger W. (1986). A monoclonal antibody against meningococcus group B polysaccharides distinguishes embryonic from adult N-CAM. J Cell Biol 103: 2429-2437
53. Saukkonen K, Haltia M, Frosch M, Bitter-Suerman D, Leinonen M. (1986). Antibodies to the capsular polysaccharide of Neisseria meningitidis group B or E. coli K1 bind to the brains of infant rats in vitro but not in vivo. Microb Pathog 1: 101-105
54. Schifferle RE, Jennings HJ, Wessels MR, Katzenellenbogen E, Roy R, Kasper DL. (1985). Immunochemical analysis of the types Ia and Ib group B streptococcal polysaccharides. J Immunol 135: 4164-4170
55. Troy FA. (1992). Polysialylation: from bacteria to brains. Glycobiology 2: 5-23
56. Wessels MR, Munoz A, Kasper DL (1987a) A model of high-affinity antibody binding to type III group B Streptococcus capsular polysaccharide. Proc Natl Acad Sci USA 84: 9170-9174
57. Wessels MR, Pozsgay V, Kasper DL, Jennings HJ (1987b) Structure and immunochemistry of an oligosaccharide repeating unit of the capsular polysaccharide of type III group B Streptococcus. A revised structure for the type III group B streptococcal polysaccharide antigen. J Biol Chem 262: 8262-8267
58. Wessels MR, Paoletti LC, Kasper DL, DiFabio JL, Michon F, Holme K, Jennings HJ. (1990). Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus. J Clin Invest 86: 1428-1433
59. Wyle FA, Artenstein MS, Brandt BL, Tramont EC, Kasper DL, Altieri PL, Berman SL, Lowenthal JP. (1972). Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis 126: 514-521
60. Zou W, MacKenzie R, Therien L, Hirama T, Yang QL, Gidney MA, Jennings HJ. (1999). Conformational epitope of the type III group B Streptococcus capsular polysaccharide. J Immunol 163: 820-825